Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial
Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following
A medicine company decided on the right amount of their new drug to give patients in an important test. When doctors narrow down to one dose, it means the medicine is moving forward in a careful, organized way.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.